Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.1
Label safety data
*In 5 clinical studies of dry eye disease with lifitegrast ophthalmic solution, 1401 patients received at least one dose of lifitegrast (1287 of which received Xiidra). The majority of patients (84%) had up to 3 months of treatment exposure. 170 patients were exposed to Xiidra for approximately 12 months.1
Across 5 clinical studies, the most common adverse
reactions (reported in 5-25% of patients) were
instillation site irritation, dysgeusia, and reduced
SONATA safety study information
†The 1-year, multicenter, randomized, prospective, double-masked, placebo-controlled, phase 3 SONATA study evaluated the safety of Xiidra compared to vehicle in 331 adult patients who had a self-reported history of dry eye disease. The most common treatment-emergent adverse reactions (>5%) in either treatment group were instillation-site irritation, instillation-site reaction, reduced visual acuity, dry eye, and dysgeusia.2
Artificial tear use was assessed as an exploratory end point.2
‡Adverse events occurring in >5% of participants in either treatment group.
§Percentage value indicates the proportion of participants who experienced each type of adverse event. Values inside bars=number of participants.